GLP-1s for diabetes may increase risk for psoriatic disease vs DPP-4 inhibitors

Patients who were prescribed GLP-1 receptor agonists for type 2 diabetes demonstrated increased risks for psoriatic arthritis, psoriasis and autoimmune thyroiditis vs. those treated with dipeptidyl peptidase-4 inhibitors, according to data.However, the researchers, who published their findings in ACR Open Rheumatology, additionally found that GLP-1 drugs for diabetes were associated with lower

Raccontata dahealio.com